Stock Region Penny Picks
Stock Region Penny Picks Newsletter - Wednesday, September 3rd, 2025 Market Watch.
Stock Region Penny Picks Newsletter - Wednesday, September 3rd, 2025 Market Watch
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimers: The information in this newsletter is for educational and entertainment purposes only. This is not financial advice, and I'm not a licensed financial advisor. Always do your own research and consult with a qualified professional before making investment decisions. Past performance doesn't guarantee future results, and all investments carry risk of loss.
Hey Stock Region family! 👋
What a day it's been in the markets! I've been glued to my screens watching some fascinating developments unfold, and honestly, I couldn't wait to share my thoughts with you. Grab your coffee (or whatever keeps you caffeinated) because we've got some serious moves to discuss.
🧠 The Brain Game: PMN's Alzheimer's Breakthrough
$PMN (ProMIS Neurosciences) just got the green light from their Data Safety Monitoring Board to advance to the final dose escalation cohort in their Phase 1b Alzheimer's trial. I've got to say, this hits close to home for me - watching family members battle this disease makes every advancement feel personal.
The fact that they're moving to final dose escalation tells me the safety profile looks solid so far. This is huge in the biotech space, where one safety concern can derail years of work. My gut? This could be a sleeper hit if their efficacy data matches their safety profile.
🦠 Silicon Power Play
$SINT dropped some fascinating news about silicon nitride showing antiviral activity against multiple virus strains, including our old nemesis SARS-CoV-2. As someone who lived through the pandemic chaos, anything that shows broad-spectrum antiviral activity gets my attention immediately.
The peer-review publication is key here - it's not just a press release claiming miracle cures. Real science, real data. Though let's be honest, we've seen plenty of "breakthrough" antiviral stories that didn't pan out. I'm cautiously optimistic but definitely keeping this on my radar.
🤖 AI Gets Personal
$LCFY (Locafy) is making me a believer in AI sales teams. Their pilot campaign generated 18 meetings and 130 warm leads - those aren't vanity metrics, folks. That's real business development happening.
Here's what excites me: they're targeting 55,000 U.S. agencies. That's a massive addressable market, and if their AI can replicate these early results at scale... well, let's just say traditional sales teams might want to update their resumes. I'm genuinely impressed by these numbers.
💼 Deal Making and Compliance Drama
$BTBD is combining with Aero Velocity in an all-stock deal. Consolidation plays can be tricky - sometimes 1+1=3, sometimes it equals 0.5. Without more details on synergies and integration plans, I'm taking a wait-and-see approach.
Meanwhile, $ADIL got a 180-day extension from Nasdaq to meet minimum bid requirements. Been there, seen that. These compliance extensions can be lifelines or just delayed executions. The clock's ticking, and they need to deliver something meaningful to justify their listing.
🚀 Defense Tech Gets Interesting
$VWAV partnering with AIPHEX for defense and space tech? Now we're talking my language! "Combat-proven" technologies entering civilian markets often create compelling investment opportunities. Think GPS, internet, even duct tape - military innovations have a way of finding profitable civilian applications.
❤️ Heart Attack Game Changer?
$ASBP announcing breakthrough results for sublingual aspirin in heart attacks has me genuinely excited. As someone who's had family members suffer heart attacks, anything that can improve treatment outcomes gets my full attention. The sublingual delivery could be a real differentiator - faster absorption, quicker action when every second counts.
📊 Numbers Don't Lie (Or Do They?)
$TLYS beat earnings expectations by 350% but missed revenue targets. Classic case of managing expenses better than generating sales. The 7% year-over-year revenue decline concerns me more than the earnings beat impresses me. Growth is the name of the game, folks.
$BRIA declared a $0.13 dividend with a 3.03% yield. In this market, yield plays are looking more attractive by the day. Sometimes boring dividend stocks are exactly what portfolios need.
🩺 Diabetes Care Evolution
$SENS signing with Ascensia for Eversense 365 distribution is smart partnering. The continuous glucose monitoring space is exploding, and having an experienced partner handle commercialization lets SENS focus on what they do best - innovation.
My Take on Today's Action
If I'm being completely honest, today felt like a mixed bag with some genuine bright spots. The biotech plays (PMN, SINT, ASBP) all showed different aspects of why I love this sector - real science solving real problems. The AI angle from LCFY has me rethinking how sales will evolve.
What's got me most excited? The convergence of healthcare innovation and AI efficiency. We're living through a transformation that'll define the next decade of investing.
What I'm watching: How these companies execute on their promises over the next 90 days. Press releases are great, but results pay the bills.
Final Reminder: Remember, I'm sharing my personal observations and opinions, not giving financial advice. The market can be unpredictable, and what looks promising today might disappoint tomorrow. Never invest more than you can afford to lose, and always do your own research. Stay smart, stay cautious, and may your coffee be strong and your gains be stronger!
Questions? Thoughts? Hit me up - I love hearing from fellow market watchers!